Header Logo

Connection

GARABED EKNOYAN to Renal Dialysis

Back to Details
This is a "connection" page, showing publications GARABED EKNOYAN has written about Renal Dialysis.
GARABED EKNOYAN
Connection Strength
4.035
Renal Dialysis
  1. A historical perspective of how public policy shaped dialysis care delivery in the United States. Semin Dial. 2020 01; 33(1):5-9.
    View in: PubMed
    Score: 0.400
  2. Uremia: A historical reappraisal of what happened?. Clin Nephrol. 2018 May; 89(5):305-313.
    View in: PubMed
    Score: 0.355
  3. The wonderful apparatus of John Jacob Abel called the "artificial kidney". Semin Dial. 2009 May-Jun; 22(3):287-96.
    View in: PubMed
    Score: 0.190
  4. Progress and promise in the management of chronic kidney disease. CMAJ. 2008 Nov 18; 179(11):1107-8.
    View in: PubMed
    Score: 0.185
  5. Artificial kidneys: progress and promise. Lancet. 2007 Dec 15; 370(9604):1977-8.
    View in: PubMed
    Score: 0.173
  6. Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol. 2006 Feb; 17(2):546-55.
    View in: PubMed
    Score: 0.151
  7. Introduction: Adequacy of dialysis: problems and challenges. Semin Nephrol. 2005 Mar; 25(2):67-9.
    View in: PubMed
    Score: 0.143
  8. The Dialysis Outcomes and Practice Patterns Study (DOPPS) and the Kidney Disease Outcomes Quality Initiative (K/DOQI): a cooperative initiative to improve outcomes for hemodialysis patients worldwide. Am J Kidney Dis. 2004 Nov; 44(5 Suppl 2):1-6.
    View in: PubMed
    Score: 0.139
  9. Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study. J Am Soc Nephrol. 2003 Dec; 14(12):3251-63.
    View in: PubMed
    Score: 0.131
  10. Practice recommendations for the use of L-carnitine in dialysis-related carnitine disorder. National Kidney Foundation Carnitine Consensus Conference. Am J Kidney Dis. 2003 Apr; 41(4):868-76.
    View in: PubMed
    Score: 0.125
  11. On the evolving nature of understanding dialysis-related disorders. Am J Kidney Dis. 2003 Apr; 41(4 Suppl 4):S1-3.
    View in: PubMed
    Score: 0.125
  12. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002 Dec 19; 347(25):2010-9.
    View in: PubMed
    Score: 0.122
  13. Continuous quality improvement: DOQI becomes K/DOQI and is updated. National Kidney Foundation's Dialysis Outcomes Quality Initiative. Am J Kidney Dis. 2001 Jan; 37(1):179-194.
    View in: PubMed
    Score: 0.107
  14. NKF-K/DOQI Clinical Practice Guidelines: Update 2000. Foreword. Am J Kidney Dis. 2001 Jan; 37(1 Suppl 1):S5-6.
    View in: PubMed
    Score: 0.107
  15. Design and statistical issues of the hemodialysis (HEMO) study. Control Clin Trials. 2000 Oct; 21(5):502-25.
    View in: PubMed
    Score: 0.105
  16. The dialysis outcomes quality initiative: history, impact, and prospects. Am J Kidney Dis. 2000 Apr; 35(4 Suppl 1):S69-75.
    View in: PubMed
    Score: 0.101
  17. Implementation of NKF-DOQI: a progress report. Nephrol News Issues. 1999 May; 13(5):11-5, 43.
    View in: PubMed
    Score: 0.095
  18. Lessons from the Hemodialysis (HEMO) Study: an improved measure of the actual hemodialysis dose. Am J Kidney Dis. 1999 Jan; 33(1):142-9.
    View in: PubMed
    Score: 0.093
  19. Cardiovascular mortality and morbidity in dialysis patients. Miner Electrolyte Metab. 1999 Jan-Apr; 25(1-2):100-4.
    View in: PubMed
    Score: 0.093
  20. The National Kidney Foundation Dialysis Outcomes Quality Initiative. Curr Opin Nephrol Hypertens. 1997 Nov; 6(6):520-3.
    View in: PubMed
    Score: 0.086
  21. A History of Uremia Research. J Ren Nutr. 2017 11; 27(6):449-452.
    View in: PubMed
    Score: 0.086
  22. Predictors of sudden cardiac death: a competing risk approach in the hemodialysis study. Clin J Am Soc Nephrol. 2012 Jan; 7(1):123-30.
    View in: PubMed
    Score: 0.057
  23. ?-Blockers for prevention of sudden cardiac death in patients on hemodialysis: a propensity score analysis of the HEMO Study. Am J Kidney Dis. 2011 Dec; 58(6):939-45.
    View in: PubMed
    Score: 0.056
  24. Obesity and chronic kidney disease. Nefrologia. 2011; 31(4):397-403.
    View in: PubMed
    Score: 0.055
  25. Disordered mineral metabolism in hemodialysis patients: an analysis of cumulative effects in the Hemodialysis (HEMO) Study. Am J Kidney Dis. 2008 Sep; 52(3):531-40.
    View in: PubMed
    Score: 0.045
  26. Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2008 Nov; 74(10):1237-40.
    View in: PubMed
    Score: 0.045
  27. Association between serum 2-microglobulin level and infectious mortality in hemodialysis patients. Clin J Am Soc Nephrol. 2008 Jan; 3(1):69-77.
    View in: PubMed
    Score: 0.043
  28. Obesity, diabetes, and chronic kidney disease. Curr Diab Rep. 2007 Dec; 7(6):449-53.
    View in: PubMed
    Score: 0.043
  29. Inflammation and inverse associations of body mass index and serum creatinine with mortality in hemodialysis patients. J Ren Nutr. 2007 Nov; 17(6):372-80.
    View in: PubMed
    Score: 0.043
  30. The Kidney Disease: improving Global Outcomes website: comparison of guidelines as a tool for harmonization. Kidney Int. 2007 May; 71(10):1054-61.
    View in: PubMed
    Score: 0.041
  31. Kidney disease: wherefore, whence, and whereto? Kidney Int. 2007 Mar; 71(6):473-5.
    View in: PubMed
    Score: 0.041
  32. Hemodialysis timing, survival, and cardiovascular outcomes in the Hemodialysis (HEMO) Study. Am J Kidney Dis. 2006 Apr; 47(4):614-24.
    View in: PubMed
    Score: 0.038
  33. Improving outcomes for dialysis patients in the international Dialysis Outcomes and Practice Patterns Study. Clin J Am Soc Nephrol. 2006 Mar; 1(2):246-55.
    View in: PubMed
    Score: 0.038
  34. Association of achieved dialysis dose with mortality in the hemodialysis study: an example of "dose-targeting bias". J Am Soc Nephrol. 2005 Nov; 16(11):3371-80.
    View in: PubMed
    Score: 0.037
  35. The HEMO Study: applicability and generalizability. Nephrol Dial Transplant. 2005 Feb; 20(2):278-84.
    View in: PubMed
    Score: 0.035
  36. Side effects of hemodialysis. N Engl J Med. 1984 Oct 04; 311(14):915-7.
    View in: PubMed
    Score: 0.035
  37. Dialysis dose and the effect of gender and body size on outcome in the HEMO Study. Kidney Int. 2004 Apr; 65(4):1386-94.
    View in: PubMed
    Score: 0.033
  38. Meeting the challenges of the new K/DOQI guidelines. Am J Kidney Dis. 2003 Jun; 41(5 Suppl):3-10.
    View in: PubMed
    Score: 0.032
  39. The Armenian earthquake of 1988: a milestone in the evolution of nephrology. Adv Ren Replace Ther. 2003 Apr; 10(2):87-92.
    View in: PubMed
    Score: 0.031
  40. Seasonal variations in clinical and laboratory variables among chronic hemodialysis patients. J Am Soc Nephrol. 2002 Sep; 13(9):2345-52.
    View in: PubMed
    Score: 0.030
  41. Methods used to evaluate the quality of evidence underlying the National Kidney Foundation-Dialysis Outcomes Quality Initiative Clinical Practice Guidelines: description, findings, and implications. Am J Kidney Dis. 2000 Jul; 36(1):1-11.
    View in: PubMed
    Score: 0.026
  42. Does the choice of renal replacement therapy adversely affect the hypercoagulability associated with renal disease? Am J Nephrol. 1998; 18(3):175-8.
    View in: PubMed
    Score: 0.022
  43. Dose and adequacy. Perit Dial Int. 1997; 17 Suppl 3:S40-1.
    View in: PubMed
    Score: 0.020
  44. International dialysis aid in earthquakes and other disasters. Kidney Int. 1993 Sep; 44(3):479-83.
    View in: PubMed
    Score: 0.016
  45. "Over-flow ascites" - the safety valve of the volume-expanded patient on dialysis. Proc Clin Dial Transplant Forum. 1973; 3:156-61.
    View in: PubMed
    Score: 0.015
  46. Both low muscle mass and low fat are associated with higher all-cause mortality in hemodialysis patients. Kidney Int. 2010 Apr; 77(7):624-9.
    View in: PubMed
    Score: 0.012
  47. Biochemical abnormalities of platelets in renal failure. Evidence for decreased platelet serotonin, adenosine diphosphate and Mg-dependent adenosine triphosphatase. Am J Nephrol. 1981; 1(1):17-23.
    View in: PubMed
    Score: 0.007
  48. Effects of renal failure on leukotaxis. J Med. 1979; 10(4):267-78.
    View in: PubMed
    Score: 0.006
  49. Minocycline and doxycycline kinetics in chronic renal failure. Clin Pharmacol Ther. 1978 Aug; 24(2):233-9.
    View in: PubMed
    Score: 0.006
  50. Indomethacin treatment of pericarditis in chronic hemodialysis patients. Arch Intern Med. 1975 Jun; 135(6):807-10.
    View in: PubMed
    Score: 0.005
  51. Malignant hypertension. Recovery of kidney function after renal allograft failure. Arch Intern Med. 1975 Feb; 135(2):300-3.
    View in: PubMed
    Score: 0.004
  52. The acute renal failure syndrome. Tex Med. 1974 Dec; 70(12):83-90.
    View in: PubMed
    Score: 0.004
  53. Human parotid saliva urea in renal failure and during dialysis. Arch Oral Biol. 1977; 22(2):83-6.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.